PAtophysiological, Nodal-based Approach for Crohn's Disease Excision

NCT ID: NCT04623476

Last Updated: 2020-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-16

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single centre prospective pilot study on surgery for Crohn's disease (CD). CD universally recurs after surgery and no technique so far has been proven to reduce recurrence.

The investigators speculate that a different surgical technique, based on pathophysiology of the disease may prove successful in reducing rates of recurrence.

Consecutive CD patients with a surgical indication for ileocolic disease will receive an extended procedure including a lymphadenectomy (Pathophysiologic excision for Crohn's disease).

Primary outcome will be endoscopic recurrence rates at 6 and 12 months from surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease Crohn's Ileocolitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Prospective pilot study
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pathophysiological Excision for Chron's disease

Consecutive patients (\>18 years old) with a surgical indication for ileocolic Crohn's disease, at their first operation for CD

Group Type EXPERIMENTAL

Pathophysiological Excision for Crohn's disease

Intervention Type PROCEDURE

Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pathophysiological Excision for Crohn's disease

Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PEC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All consecutive patients undergoing surgery for ileocaecal/ileocolic CD in the Minimally Invasive Unit at Policlinico Tor Vergata are eligible to be enrolled.
* Informed consent

Exclusion Criteria

* Crohn's Disease with a different localisation
* Recurrent disease
* Extensive jejunitis
* \<18 years of age
* Cancer as primary indication for surgery
* Followed by gastroenterologists outside our centre, due to loss of follow up
* Ileostomy. If a patient undergoes ileostomy fashioning he will be excluded from the study and this will be reported
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Rome Tor Vergata

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Giuseppe Sigismondo Sica

Associate Professor, Head of Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Giuseppe S Sica, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Università di Roma Tor Vergata

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Policlinico Tor Vergata

Roma, RM, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bruno Sensi, MD

Role: CONTACT

Phone: 3385352902

Email: [email protected]

Giuseppe S Sica, MD, PhD

Role: CONTACT

Phone: 3385333659

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bruno Sensi, MD

Role: primary

Giuseppe S Sica, MD, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

112/20

Identifier Type: -

Identifier Source: org_study_id